Study Details

Back to Search Results

Phase 1 trial of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR)

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02054351

Astellas Study ID

The unique identification code given by the study sponsor.

GM-IMAB-002-01

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2013-002755-15

Follow Trial

Condition

Ovarian Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 Years - N/A

Sex

Female

Product

ASP1650

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Feb 2014 - Oct 2015

Masking

None (Open Label)

Enrollment number

42

A first-in-human dose escalation and dose finding Phase 1 trial of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Phase 1 trial of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

UZ Brussels

Brussels, Belgium, 1090

UZ Leuven

Leuven, Belgium, 3000

Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Universitätsklinikum Heidelberg

Heidelberg, Germany, 69120

Universitäts-Frauenklinik (UFK) Tübingen

Tübingen, Germany, 72076

Universitätsklinikum Ulm, Frauenklinik

Ulm, Germany, 89075

Charité - Universitätsmedizin Berlin

Berlin, Germany, 13353

Universitätsmedizin Mainz

Mainz, Germany, 55131

Gemeinschaftspraxis Hämatologie-Onkologie

Dresden, Germany, 1307

UKSH Kiel

Kiel, Germany, 24105

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo